Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis

In a phase 2 trial involving 166 patients with moderate-to-severe plaque psoriasis, risankizumab, a humanized monoclonal antibody that selectively inhibits IL-23, achieved clinical response superior to that achieved with ustekinumab, an IL-12 and IL-23 inhibitor. Psoriasis is a chronic immune-mediat...

Ausführliche Beschreibung